✨ Free AI Report
Prothena Corporation plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Prothena Corporation plc
Company Research

Prothena Corporation plc: Business Overview, Financials & Competitive Analysis

Prothena Corporation plc scores 5/10 on the AskCyborg Cyborg Score (Mixed). Prothena's strategic collaborations and commitment to addressing unmet medical needs position it as a significant player in neuroscience therapy development with an innovative approach to improve patient outcomes, but financial sustainability depends on clinical milestone achievements and partnership success.

What is Prothena Corporation plc's industry? Prothena Corporation plc (prothena.com) operates in Biotechnology - Clinical Stage Neurodegenerative Diseases. AskCyborg classifies Prothena Corporation plc under Biotechnology - Clinical Stage Neurodegenerative Diseases in its company registry.

Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. With expertise in protein dysregulatio...

5/ 10Mixed

Cyborg Score thesis

Prothena's strategic collaborations and commitment to addressing unmet medical needs position it as a significant player in...

Read the full analyst-debate transcript →
Industry Biotechnology - Clinical Stage Neurodegenerative Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Prothena Corporation plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Prothena Corporation plc

AskCyborg analysts argue the bull and bear cases for Prothena Corporation plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Prothena Corporation plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Prothena Corporation plc Overview

Pro stress-test →

Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. With expertise in protein dysregulation, the company is advancing a pipeline of both wholly-owned and partnered programs for potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Strategic Profile

Pro stress-test →

Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company has strategic partnerships with F. Hoffmann-La Roche Ltd. to develop and commercialize antibodies targeting a-synuclein (prasinezumab) and with Bristol Myers Squibb for antibodies targeting tau and TDP-43. As of December 31, 2025, Prothena holds $308.4M in cash with no debt and expects $255M at year-end 2026.

Competitive Landscape

Pro stress-test →

Prothena operates in the biotechnology sector focusing on discovery and development of innovative therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. Key competitors include larger pharma companies (Eli Lilly, Biogen) and smaller biotech firms (Denali Therapeutics, Alector Inc.) pursuing similar neurodegenerative disease targets, particularly Alzheimer's and Parkinson's programs.

Industry Context

Prothena Corporation plc operates in Biotechnology - Clinical Stage Neurodegenerative Diseases.

Key facts

Founded: 2012 · Headquarters: Dublin, Ireland · Revenue: $9.68M · Market cap: $485.55M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Prothena Corporation plc.

  • Lead program Prasinezumab is in phase 2b clinical trial for Parkinson's disease and synucleinopathies
  • Up to $105M in potential clinical milestone payments from Novo Nordisk (coramitug) and Bristol Myers Squibb (PRX019) in 2026
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced $100M share repurchase program and reported Q4 2025 narrower loss but revenue miss
  • February 2026Provided 2026 cash burn guidance and highlighted potential milestone payments from strategic partners
  • +1 moreTrack every material event for Prothena Corporation plc as it happens. Explore monitoring →
Get alerted when Prothena Corporation plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DonanemabAlzheimer's disease immunotherapy→LecanemabAlzheimer's disease amyloid-targeting therapy→Denali Therapeutics ProgramsNeurodegenerative disease focus→

Compare Prothena Corporation plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Prothena Corporation plc operates in Biotechnology - Clinical Stage Neurodegenerative Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Clinical Stage Neurodegenerative Diseases research →
NEW · MCP server

Ask your AI assistant about Prothena Corporation plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Prothena Corporation plc and its top competitor on Cyborg Score”
“What did Prothena Corporation plc do this quarter?”
“Is Prothena Corporation plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Prothena Corporation plc do?+
Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. With expertise in protein dysregulatio...
What is Prothena Corporation plc's Cyborg Score?+
Prothena Corporation plc has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Prothena Corporation plc's main competitors?+
Named competitors include Donanemab, Lecanemab, Denali Therapeutics Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Prothena Corporation plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Prothena Corporation plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Prothena Corporation plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.